Graham Jackson

Professor Graham Jackson is a distinguished Professor of Haematology at Newcastle University's Faculty of Medical Sciences, where he has established himself as a leading researcher in multiple myeloma and hematological malignancies. His work primarily focuses on genetic profiling, clinical trial design, and improving treatment outcomes for myeloma patients through large-scale studies including the landmark Myeloma XI trial.

Professor Jackson's research interests center on multiple myeloma, with particular emphasis on genetic risk stratification, clinical trial design, and optimizing treatment protocols for both transplant-eligible and transplant-ineligible patients. His work has significantly contributed to understanding the role of cytogenetic abnormalities, minimal residual disease monitoring, and the development of risk prediction models such as the UK Myeloma Research Alliance Risk Profile (MRP). His research spans from basic science investigations into the molecular mechanisms of myeloma to large-scale clinical trials that directly impact patient care.

Analysis of Professor Jackson's extensive publication record reveals a clear trend toward increasingly sophisticated genetic and molecular profiling of myeloma patients. His recent work demonstrates a shift toward personalized medicine approaches, incorporating genomic data to predict treatment response and optimize therapeutic strategies. He has been instrumental in major clinical trials including the Myeloma XI study, which has transformed treatment paradigms for multiple myeloma, particularly in areas like maintenance therapy, risk-adapted treatment, and management of high-risk disease.

Professor Jackson has received significant research funding from organizations including the Medical Research Council, Cancer Research UK, Celgene, and Amgen. His work on the development and validation of the UK Myeloma Research Alliance Risk Profile (MRP) has provided clinicians with a valuable tool for predicting outcomes in transplant-ineligible myeloma patients. His contributions to understanding the impact of the COVID-19 pandemic on myeloma diagnosis and treatment have also been particularly timely and relevant.

As a principal investigator on numerous clinical trials, Professor Jackson has mentored many researchers in the field of hematology. His collaborative approach is evident in the extensive list of co-authors across his publications, reflecting partnerships with leading institutions and researchers worldwide. His work continues to shape clinical practice guidelines and improve outcomes for patients with multiple myeloma.